MA45231A - Anticorps anti-ige - Google Patents

Anticorps anti-ige

Info

Publication number
MA45231A
MA45231A MA045231A MA45231A MA45231A MA 45231 A MA45231 A MA 45231A MA 045231 A MA045231 A MA 045231A MA 45231 A MA45231 A MA 45231A MA 45231 A MA45231 A MA 45231A
Authority
MA
Morocco
Prior art keywords
ige
body anti
Prior art date
Application number
MA045231A
Other languages
English (en)
Inventor
Ralph Adams
Thomas Allen Ceska
Anna Marie Davies
Alistair James Henry
Xiaofeng Liu
James Michael Mcdonnell
Brian John Sutton
Marta Katarzyna Westwood
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of MA45231A publication Critical patent/MA45231A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
MA045231A 2016-06-10 2017-06-08 Anticorps anti-ige MA45231A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1610198.2A GB201610198D0 (en) 2016-06-10 2016-06-10 Anti-ige antibodies
GBGB1702435.7A GB201702435D0 (en) 2016-06-10 2017-02-15 Anti-ige antibodies

Publications (1)

Publication Number Publication Date
MA45231A true MA45231A (fr) 2021-05-05

Family

ID=56894897

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045231A MA45231A (fr) 2016-06-10 2017-06-08 Anticorps anti-ige

Country Status (26)

Country Link
US (2) US11214627B2 (fr)
EP (1) EP3468995A1 (fr)
JP (2) JP7164439B2 (fr)
KR (1) KR102456813B1 (fr)
CN (1) CN109379892B (fr)
AR (1) AR108707A1 (fr)
AU (1) AU2017277600A1 (fr)
BR (1) BR112018074838A2 (fr)
CA (1) CA3027120A1 (fr)
CL (2) CL2018003556A1 (fr)
CO (1) CO2018013006A2 (fr)
EA (1) EA201990004A1 (fr)
EC (1) ECSP19001438A (fr)
GB (2) GB201610198D0 (fr)
IL (2) IL263452B2 (fr)
MA (1) MA45231A (fr)
MX (1) MX2018014761A (fr)
PE (1) PE20190212A1 (fr)
PH (1) PH12018502574A1 (fr)
SG (1) SG11201810199WA (fr)
TN (1) TN2018000423A1 (fr)
TW (1) TW201802114A (fr)
UA (1) UA126468C2 (fr)
UY (1) UY37290A (fr)
WO (1) WO2017211928A1 (fr)
ZA (2) ZA201807822B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY37377A (es) * 2016-08-26 2018-03-23 Sanofi Sa Anticuerpos multiespecíficos que facilitan el emparejamiento selectivo de cadenas ligeras
EP3774925A1 (fr) 2018-04-13 2021-02-17 Institut national de la santé et de la recherche médicale (INSERM) Anticorps anti-ige humains modifiés par fc et procédés d'utilisation
MX2021004351A (es) * 2018-10-16 2021-05-31 UCB Biopharma SRL Metodo para el tratamiento de miastenia grave.
GB2589049C (en) * 2019-04-11 2024-02-21 argenx BV Anti-IgE antibodies
BR112022000416A2 (pt) * 2019-07-11 2022-03-03 Wuhan Yzy Biopharma Co Ltd Anticorpo biespecífico, composição farmacêutica, conjugado, polinucleotídeo, célula e usos do anticorpo biespecífico
CN113372450A (zh) * 2020-03-10 2021-09-10 北京万华生物工程有限公司 IgE嵌合性双特异性抗体制备及应用
US20230183810A1 (en) * 2020-05-04 2023-06-15 Dna-Seq, Inc. Methods and systems for determination of an effective therapeutic regimen and drug discovery
WO2021250546A1 (fr) 2020-06-09 2021-12-16 University Of Washington Micro-arn en tant que prédicteurs de réponse à des thérapies anti-ige dans l'urticaire chronique spontanée
CN111875706B (zh) * 2020-07-16 2021-03-30 广州康盛生物科技股份有限公司 一种抗人IgE蛋白的单域抗体及其应用
WO2022061236A1 (fr) * 2020-09-21 2022-03-24 The Board Of Trustees Of The Leland Stanford Junior University Anticorps anti-ige à haute affinité
TW202332691A (zh) * 2021-10-12 2023-08-16 聯合生物製藥股份有限公司 Ige調節的疾病的治療
WO2023070502A1 (fr) * 2021-10-29 2023-05-04 天辰生物医药(苏州)有限公司 Protéine de liaison à un antigène isolée et son utilisation
CN114028569B (zh) * 2021-12-20 2023-04-28 中国医学科学院基础医学研究所 免疫球蛋白IgE在诊断和/或治疗高血压中的用途
CN114504644B (zh) * 2021-12-24 2024-02-13 北京大学第一医院 抗IgE抗体在用于治疗腺样体肥大中的应用
WO2024003376A1 (fr) * 2022-07-01 2024-01-04 Alk-Abelló A/S Dispositifs de déplacement d'ige-fceri
CN116143932A (zh) * 2022-12-07 2023-05-23 南开大学 一种针对IgE的抗体或其抗原结合片段以及Fc变体
CN116754773B (zh) * 2023-05-15 2024-06-07 江南大学 一种免疫球蛋白e的检测试剂盒

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
EP1186660A3 (fr) 1985-03-30 2002-03-20 KAUFFMAN, Stuart A. Procédé d'obtension d'ADN, ARN, peptides, polypeptides ou protéines, par une technique de recombination d'ADN
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
DE3600905A1 (de) 1986-01-15 1987-07-16 Ant Nachrichtentech Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5763192A (en) 1986-11-20 1998-06-09 Ixsys, Incorporated Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
CA2016842A1 (fr) 1989-05-16 1990-11-16 Richard A. Lerner Methode pour puiser dans le repertoire immunologique
CA2016841C (fr) 1989-05-16 1999-09-21 William D. Huse Methode de production de polymeres ayant une activite choisie
EP0478627A4 (en) 1989-05-16 1992-08-19 William D. Huse Co-expression of heteromeric receptors
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0542810A1 (fr) 1990-08-02 1993-05-26 B.R. Centre Limited Procedes de production de proteines presentant une fonction souhaitee
EP0519596B1 (fr) 1991-05-17 2005-02-23 Merck & Co. Inc. Procédé pour réduire l'immunogénicité des domaines variables d'anticorps
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
EP1400536A1 (fr) 1991-06-14 2004-03-24 Genentech Inc. Procédé pour fabriquer des anticorps humanisés
JP3457962B2 (ja) 1991-08-14 2003-10-20 ジェネンテク，インコーポレイテッド 特定Ｆｃεレセプターのための免疫グロブリン変異体
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
US5766886A (en) 1991-12-13 1998-06-16 Xoma Corporation Modified antibody variable domains
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
ZA966075B (en) 1995-07-27 1998-01-19 Genentech Inc Protein formulation.
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
AU716785B2 (en) 1995-07-27 2000-03-09 Genentech Inc. Stabile isotonic lyophilized protein formulation
ZA971607B (en) * 1996-03-12 1998-08-25 Univ Johns Hopkins Methods of treatment of allergic diseases
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US6172213B1 (en) * 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
JP2002501905A (ja) * 1998-01-29 2002-01-22 タノックス インコーポレイテッド ＩｇＥアンタゴニストによるアトピー性皮膚炎の治療
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
AU5020700A (en) * 1999-05-26 2000-12-18 Tanox, Inc. Treating allergic diseases with immunotherapy and ige antagonists
AU2001268855A1 (en) 2000-05-26 2001-12-03 National Research Council Of Canada Single-domain antigen-binding antibody fragments derived from llama antibodies
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
GB0129105D0 (en) 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
US7993864B2 (en) 2002-12-03 2011-08-09 Ucb Pharma S.A. Assay for identifying antibody producing cells
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
US7989594B2 (en) 2003-07-01 2011-08-02 Celltech R & D Limited Modified antibody fab fragments
WO2005014655A2 (fr) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugues d'amidon d'hydroxyalkyle et de proteine
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
GB0502358D0 (en) 2005-02-04 2005-03-16 Novartis Ag Organic compounds
SG2014010029A (en) 2005-08-19 2014-08-28 Abbott Lab Dual variable domain immunoglobin and uses thereof
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
AR065921A1 (es) * 2007-04-02 2009-07-08 Amgen Fremont Inc Anticuerpos anti-ige
WO2008153926A2 (fr) * 2007-06-05 2008-12-18 Yale University Inhibiteurs de récepteurs tyrosine kinases et leurs méthodes d'utilisation
EP2535349A1 (fr) 2007-09-26 2012-12-19 UCB Pharma S.A. Fusions d'anticorps à double spécificité
EP2604628A3 (fr) 2007-12-21 2013-08-21 Medimmune Limited Éléments de liaison pour le récepteur alpha interleukin-4 (IL-4R) - 173
JP5470817B2 (ja) 2008-03-10 2014-04-16 日産自動車株式会社 電池用電極およびこれを用いた電池、並びにその製造方法
CN101230103B (zh) * 2008-03-25 2011-09-07 中国医药集团总公司四川抗菌素工业研究所 一全人源重组抗-IgE抗体
US10407513B2 (en) 2008-09-26 2019-09-10 Ucb Biopharma Sprl Biological products
EP2475682B1 (fr) 2009-09-10 2018-01-31 UCB Biopharma SPRL Anticorps multivalents
MX344935B (es) 2009-10-26 2017-01-11 Genentech Inc Analisis para detectar anticuerpos especificos a anticuerpos anti-ige terapeuticos y su uso en anafilaxis.
AU2011285852B2 (en) 2010-08-03 2014-12-11 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
SG11201401649VA (en) * 2011-11-11 2014-07-30 Ucb Pharma Sa Albumin binding antibodies and binding fragments thereof
KR20140119777A (ko) 2012-01-31 2014-10-10 제넨테크, 인크. 항-ig-e m1'' 항체 및 그의 사용 방법
US20150140608A1 (en) 2012-06-01 2015-05-21 Momenta Pharmaceuticals, Inc. Methods related to omalizumab
JP6136279B2 (ja) 2013-01-15 2017-05-31 株式会社ジェイテクト 転がり軸受装置
TWI503850B (zh) 2013-03-22 2015-10-11 Polytronics Technology Corp 過電流保護元件
US10196458B2 (en) 2013-07-26 2019-02-05 The Regents Of The University Of California Anti-immunoglobulin E antibodies and methods of using thereof
TWI510996B (zh) 2013-10-03 2015-12-01 Acer Inc 控制觸控面板的方法以及使用該方法的可攜式電腦
CN104987412A (zh) 2015-07-14 2015-10-21 上海拜豪生物科技有限公司 一种砷-IgE螯合物及其制备方法和应用
US20180273626A1 (en) * 2015-09-11 2018-09-27 The Board Of Trustees Of The Leland Stanford Junio University Omalizumab resistant ige variants and their use in anti-ige therapy
US9816280B1 (en) 2016-11-02 2017-11-14 Matthew Reitnauer Portable floor

Also Published As

Publication number Publication date
AR108707A1 (es) 2018-09-19
BR112018074838A2 (pt) 2019-03-26
KR102456813B1 (ko) 2022-10-20
JP2023021974A (ja) 2023-02-14
TW201802114A (zh) 2018-01-16
JP7164439B2 (ja) 2022-11-01
EA201990004A1 (ru) 2019-06-28
IL263452A (en) 2019-01-31
IL309516A (en) 2024-02-01
AU2017277600A2 (en) 2019-01-17
CN109379892B (zh) 2023-07-04
PH12018502574A1 (en) 2019-10-28
PE20190212A1 (es) 2019-02-07
JP2019522470A (ja) 2019-08-15
UA126468C2 (uk) 2022-10-12
GB201702435D0 (en) 2017-03-29
IL263452B2 (en) 2024-05-01
RU2019100034A3 (fr) 2020-11-20
UY37290A (es) 2018-01-31
SG11201810199WA (en) 2018-12-28
AU2017277600A1 (en) 2019-01-03
GB201610198D0 (en) 2016-07-27
US20190144565A1 (en) 2019-05-16
TN2018000423A1 (en) 2020-06-15
EP3468995A1 (fr) 2019-04-17
WO2017211928A1 (fr) 2017-12-14
ECSP19001438A (es) 2019-01-31
CL2018003556A1 (es) 2019-04-05
US20220235146A1 (en) 2022-07-28
CL2021002696A1 (es) 2022-06-03
IL263452B1 (en) 2024-01-01
ZA201807822B (en) 2020-05-27
CO2018013006A2 (es) 2019-04-30
US11214627B2 (en) 2022-01-04
KR20190017949A (ko) 2019-02-20
CA3027120A1 (fr) 2017-12-14
CN109379892A (zh) 2019-02-22
MX2018014761A (es) 2019-04-25
ZA202000803B (en) 2021-08-25
RU2019100034A (ru) 2020-07-13

Similar Documents

Publication Publication Date Title
MA46041A (fr) Anticorps anti-tim -3
MA45231A (fr) Anticorps anti-ige
MA47694A (fr) Anticorps anti-tigit
MA49034A (fr) Anticorps anti-lag3
FR21C1030I2 (fr) Conjugué anticorps anti-her2-médicament
MA47268A (fr) Anticorps anti-gpc3
MA46525A (fr) Anticorps anti-lag-3 et compositions
MA45004A (fr) Anticorps spécifiques anti-wt1-hla
MA53434A (fr) Anticorps anti-tigit
MA53297A (fr) Anticorps anti-icos
MA52884A (fr) Anticorps anti-il-11
MA46057A (fr) Anticorps anti-ctla4
MA44659A (fr) Anticorps anti-tim-3 et compositions
MA45784A (fr) Anticorps anti-idiotypes dirigés contre anti-cd19 anticorps
MA46272A (fr) Anticorps anti-cd27
MA47472A (fr) Anticorps
MA50352A (fr) Anticorps multispécifiques
DK3606961T3 (da) Garp-tgf-beta-antistoffer
MA42843A (fr) Anticorps anti-cd115
MA52366A (fr) Anticorps anti-tl1a optimisés
MA51134A (fr) Anticorps anti-alpha-synucléine
MA44236A (fr) Anticorps anti-tgfbêta 2
MA53887A (fr) Anticorps à liaison protofibrille a-bêta améliorée
MA52152A (fr) Anticorps
MA51554A (fr) Anticorps il-6 améliorés